Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Cambrex Signs Drug API Supply Deal

by Rick Mullin
August 20, 2012 | A version of this story appeared in Volume 90, Issue 34

Cambrex has signed a contract to supply an active pharmaceutical ingredient for a Phase III clinical trial program during 2013 and 2014. The pharmaceutical chemicals firm will also provide prelaunch quantities of the API. Cambrex expects the deal to contribute more than $20 million to 2013 revenues and potentially more in 2014, depending on regulatory developments and timing for the completion of a $19 million capacity expansion program for this and other projects. Describing the contract as potentially one of the biggest in Cambrex’ history, CEO Steve M. Klosk said in a conference call that his company has “been encouraged by the quality and number of late-stage clinical-phase projects that we are getting the opportunity to bid on.”

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.